Company news
Botanix Pharmaceuticals Limited (ASX:BOT) news
Botanix Pharmaceuticals Limited news releases on 6ix. Latest, Sep 4, 2026: S&P DJI Announces September 2026 Quarterly Rebalance
Press releases & updates
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
Appendix 4E & Annual Report for the Year Ended 30 June 2026
August 26, 2026
Botanix Quarterly Activities Report and Appendix 4C Q4 FY26
July 26, 2026
Notice of Allowance for US patent on Sofdra drug substance
July 12, 2026
Intention to Grant a European patent on Sofdra applicator
July 6, 2026
Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
April 28, 2026
Botanix reaches term sheet agreement with 2nd API supplier
April 15, 2026
Successful renegotiation of API supply agreement
March 29, 2026
S&P DJI Announces March 2026 Quarterly Rebalance
March 6, 2026
Appendix 4D and Half Year Report
February 27, 2026
Botanix Receives Capital Raise Commitments of A$45 Million
February 16, 2026
Trading Halt
February 13, 2026
Pause in Trading
February 13, 2026
Botanix Quarterly Activities Report and Appendix 4C Q2 FY26
January 26, 2026
Botanix Quarterly Activities Report and Appendix 4C Q1 FY26
October 19, 2025
Appendix 4E & Annual Report for the Year Ended 30 June 2025
August 29, 2025
Response to ASX Aware Letter
July 31, 2025
June 2025 Quarterly Activities Report and Appendix 4C
July 27, 2025
Botanix Provides Sofdra Launch Update
July 7, 2025
Botanix Signs Debt Facility with Kreos Capital
June 9, 2025
Response to ASX Price Query Letter
May 12, 2025
Botanix Responds to US Pharmaceutical Pricing Announcement
May 12, 2025
Pause in trading
May 12, 2025
March 2025 Quarterly Activities Report and Appendix 4C
April 24, 2025
Botanix $40 Million Capital Raising for Sofdra Rollout
April 15, 2025
Botanix Conference Commercial Update
March 10, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
December 2024 Quarterly Activities Report and Appendix 4C
January 30, 2025
First Sofdra Prescriptions as Commercialisation Ramps Up
December 16, 2024
Botanix Pharmaceuticals : Releases Quarterly Reports
October 28, 2024
September 2024 Quarterly Activities Report and Appendix 4C
October 27, 2024
Botanix Appendix 4E & Announcement of Commercial Day Webinar
August 30, 2024
June 2024 Quarterly Activities Report and Appendix 4C
July 30, 2024
Botanix $70 Million Institutional Capital Raising
June 21, 2024
FDA Approves Sofdra
June 19, 2024
Final Sofdra Labelling Discussions with FDA
June 11, 2024
March 2024 Quarterly Activities Report and Appendix 4C
April 30, 2024
S&P DJI Announces March 2024 Quarterly Rebalance
March 1, 2024
Botanix Pharmaceuticals Half Year Report
February 27, 2024
December 2023 Quarterly Activities Report and Appendix 4C
January 30, 2024
NDA Resubmission Accepted and Approval Date Confirmed
January 21, 2024
Botanix Resubmission of NDA for Sofdra Completed
December 20, 2023
Successful Completion of Human Factors Study
December 13, 2023
FDA Confirms Approach to Sofdra NDA Resubmission
December 3, 2023
Successful Completion of $13.5m Institutional Placement
November 30, 2023
Botanix Placement Secures $13.5M to Fund Sofdra Launch Prep
November 26, 2023
Investor Presentation and Investor Meetings
October 30, 2023
September 2023 Quarterly Activities Report and Appendix 4C
October 30, 2023
Presentation- FDA Letter Requires Patient Instruction Update
September 25, 2023
FDA Letter Requires Patient Instruction Update
September 25, 2023